Skin fibroblasts cultured from patients affected with the Hunter syndrome are deficient in the activity of a protein, named the "Hunter corrective factor," that is required for degradation of dermatan and heparan sulfates. We now show that this factor, purified from human urine, removes about 2% of the sulfate residues from [3aS]mucopolysaccharide accumulated within Hunter fibroblasts; these groups are derived from "oversulfated" regions of the polymer. Acetone-powder extracts of fibroblasts derived from patients with the Hunter syndrome are deficient in this sulfatase, in contrast to similar extracts from fibroblasts of individuals of other genotype. Hunter corrective factor coupled to a-L-iduronidase (or alternatively, mixed extracts from Hurler and Hunter fibroblasts) release iduronic acid from 4-0-a-L-sulfoiduronosyl-Dsulfoanhydromannose. We conclude that the Hunter corrective factor is a sulfatase for sulfated iduronic acid residues.
The Hunter syndrome is a genetic disorder associated with failure to degrade dermatan sulfate and heparan sulfate; lysosomal storage of these polymers leads to numerous clinical problems, including skeletal abnormalities, limitation of joint motion, hepatosplenomegaly, deafness, and cardiovascular disease (1, 2) . Of the known mucopolysaccharidoses, the Hunter syndrome is the only one transmitted as an X-linked recessive trait.
Fibroblasts cultured from the skin of Hunter patients do not adequately degrade sulfated mucopolysaccharide because of a deficiency of a specific protein that is present in cell secretions, cells, and urine of individuals who do not have the Hunter syndrome (3) (4) (5) . Because this protein, when added exogenously to Hunter cells, accelerates the degradation of sulfated mucopolysaccharide, it has been named the "Hunter corrective factor," and abbreviated simply as "Hunter factor." Purified Hunter factor has no effect on the mucopolysaccharide metabolism of cells derived from normal individuals or from patients with mucopolysaccharide storage disorders other than the Hunter syndrome (5) .
Several analogous corrective factors have recently been identified as the "missing enzyme" in the corresponding disorder. Thus, the Hurler corrective factor has been identified as the enzyme a-iiduronidase, and the Hurler and Scheie syndromes as a-riduronidase deficiency diseases (6, 7) ; the Sanfilippo A corrective factor has been identified as heparan sulfate sulfatase (probably an N-sulfatase) (8) , and the Sanfilippo B factor as N-acetyl-a-glucosaminidase (9, 10) . In a mucopolysaccharidosis due to #3-glucuronidase (EC 3.2.1.31) deficiency, jB-glucuronidase serves as corrective factor (11) .
We have now identified the Hunter corrective factor as a sulfatase for sulfated iduronic acid residues, which occur in $ Address reprint requests to this author.
several mucopolysaccharides (12) (13) (14) (15) . A preliminary report of this work has been presented (16 6 .0 (0) or without factor but with an equal amount of buffered saline (0) in a final volume of 0.65 ml. The reaction mixture also contained 0.1 M sodium acetate (pH 4.4) and 5 mM NaN3. Radioactive products of the incubation were separated on a column (1.5 X 80 cm) of Sephadex G-200, eluted in fractions of 2 ml with 0.9% NaCl. The small peak of totally retarded material was collected, concentrated by lyophilization, and applied to a column of BioGel P-2 (1 X 55 cm) in 1 M NaCl (Panel C); fractions of 1 ml were collected. Identical elution patterns on BioGel P-2 were obtained for the retarded material released from the dermatan sulfate and from the heparan sulfate fractions, although only the former is plotted here.
Labeled mucopolysaccharides were separated on Sephadex G-200. A major peak, appearing immediately after the void volume, contained 90% dermatan sulfate, as previously documented (5), whereas a minor, greatly retarded peak contained 75% heparan sulfate and 25% dermatan sulfate. Further purification was achieved by adsorption to DEAESephadex A-50 in 5 mM phosphate buffer (pH 7.0) and elution by discontinuous increments of NaCl in the same buffer. The heparan sulfate was eluted with 0.6 M NaCl, and the dermatan sulfate with 0.8-1.0 M NaCl.
Radioactivity. Except for corrective factor assays, for which a scintillation fluid has been stipulated (17) 10 ,l of "enriched Tris buffer" (19) and 0.05 units of chondroitinase ABC in a total volume of 0.05 ml. After 45 min at 370, another 0.05 unit of enzyme in 5 ,dI was added, and the incubation was continued for 45 min longer; the reaction was stopped by immersing the tubes in a boiling-water bath for 2 min. An aliquot was applied to Whatman 1 and subjected to descending chromatography in n-butanol-acetic acid-0.1 N NH40H (2:3: 1, v/v) for 22 hr. The paper was cut into 3-mm strips, each of which was counted in 0. 5 ml H20 and 9.5 ml of scintillation fluid.
Paper Electrophoresis. To identify inorganic sulfate, electrophoresis was performed in 0.2 M ammonium acetate buffer (pH 5.0) at 25 V/cm. Authentic ;5SO04 was applied in the same salt mixture as the unknown sample, to correct for the interference of chloride with the migration of sulfate ions.
Gas-Liquid Chromatography of Iduronic Acid. Iduronic acid was measured by gas-liquid chromatography as 1,4-idonolactone butaneboronate by the procedure of Eisenberg [(20) and manuscript in preparation]. A tube containing a known amount of barium iduronate was prepared as standard, and to this tube as well as to each unknown sample a constant amount of mannitol was added as internal standard. The samples were reduced with sodium borohydride, freed of boric acid, lactonized, and derivatized. They were then analyzed with a Beckman GC65 gas chromatograph on a column of OV17 on GasChrom Q. From the ratio of peak areas of idonolactone butaneboronate to mannitol butaneboronate, the amount of iduronic acid in each unknown sample was calculated.
RESULTS

Sulfatase activity of Hunter corrective factor
Incubation of the Hunter corrective factor with [15S]mucopolysaccharide isolated from Hunter fibroblasts resulted in the release of a small amount of material of low molecular weight (Fig. 1) . About 1.5% of the radioactivity was released from the fraction that contained primarily dermatan sulfate and 4.5% from the fraction that contained primarily heparan sulfate. In both cases, the radioactive product was shown to correspond to inorganic sulfate by chromatography on Biogel extracted from Hunter fibroblasts (about 100,000 cpm) is incubated with Hunter corrective factor, usually 5-20 units, in 0.12 M sodium acetate (pH 4.0) and 5 mM NaN3. The incubation mixture, 0.07-0.11 ml, contains, in addition, NaCl (<0.07 M) and sodium phosphate (pH 6.0) (<5 mM) that are introduced with the Hunter factor. After 20 hr at 370, 0.1 ml of chondroitin 4-sulfate (10 mg/ml in 1 M NaHCO3) and 4 volumes of absolute ethanol are added. The mixture is thoroughly agitated on a Vortex mixer, chilled in ice for 30 mim; and centrifuged at 10,000 X g for 20 min at 20. The supernatant solution is collected and again centrifuged. An aliquot of the supernatant solution and of the precipitate (redissolved in water) are counted. A control incubation without Hunter factor is carried through the same steps, and all values are corrected for this blank (usually about 300 cpm). The assay is based on preliminary experiments that showed an optimal pH at 4.0, with half maximal activity at pH 3.5 and 4.7. Citrate-phosphate buffer is inhibitory. The rate of release of ethanol-soluble material is linear for 10 hr but diminishes markedly thereafter. Sulfatase activity was assayed as described in Methods, with 2 X 105 cpm of [IS] mucopolysaccharide, and amounts of Hunter factor or normal acetone-powder extract selected to be in the linear range. Extract from Hunter fibroblasts contained 0.1 mg of protein; higher amounts gave an apparent inhibition, perhaps because of dilution of the radioactive substrate with endogenous mucopolysacchoride.
The ethanol-soluble reaction product behaves as inorganic sulfate by chromatography on Biogel P-2 and by paper electrophoresis at pH 5.0 (Rpicrate = 3.0).
Up to a point, there is a linear relationship between the amount of Hunter factor added and the amount of '5SO4= released (Fig. 2) Table 2 ). The Hunter genotype, shown to be associated with deficiency of Hunter factor, is now correlated with a deficiency of sulfatase activity. An interesting exception to that correlation is the marked deficiency of sulfatase in extracts of fibroblasts from I-cell disease patients (Table 1 ). These cells have markedly reduced activity of several lysosomal enzymes (e.g., ref. 21) and are unable to correct the defect of Hunter fibroblasts (4) .
Homogenates prepared by freeze-thawing of fibroblasts, were found unsatisfactory for studying the sulfatase because of the presence of apparent inhibitors, particularly in homogenates of normal cells. The interfering substances are presumably removed in the preparation of acetone powders. Incubation mixtures contained 0.2 jumol of disaccharide; acetonepowder extract in 0.9% NaCl containing about 0.1 mg of protein; a final concentration of 0.12 M sodium acetate buffer (pH 4.0) and 5 mM NaNs, in a total volume of 70 ul. After 24 hr at 370, the iduronate released was measured by gas-liquid chromatography, as described in Methods. Higher amounts of acetone-powder extracts resulted in apparent inhibition in the mixed sample, perhaps because of its high content of endogenous mucopolysaccharide.
disulfated5. After treatment of the [a5S]mucopolysaccharide
with Hunter factor, the proportion of disulfated disaccharides produced by chondroitinase ABC was reduced to a limiting value of about 5% (Table 3) . Apparently, one-third of the "oversulfated" areas of mucopolysaccharide isolated from Hunter fibroblasts was removed by the Hunter factor. By contrast, mucopolysaccharide isolated from Hurler fibroblasts and similarly treated with chondroitinase ABC, showed the presence of about 4% oversulfated areas, none of which was removed by the Hunter factor (4.1 or 4.5%, for control sample or sample treated with Hunter factor, respectively).
These results are consistent with the hypothesis that the Hunter corrective factor is a sulfatase for oversulfated areas of the mucopolysaccharide, provided these are suitably exposed. Since the sulfate residue that is unique to such areas is that linked to L-iduronic acid, the results further suggest that the Hunter factor is a sulfatase for sulfated iduronic acid. A direct demonstration thereof was obtained by using for substrate the disaccharide 4-0-a-L-sulfoiduronosyl-Dsulfoanhydromannose, and measuring iduronic acid released by the combined action of Hunter factor and a-Liduronidase. Whereas either enzyme alone released only traces of iduronic acid, as determined by gas-liquid chromatography, the two enzymes together released as much as 40% of the available iduronic acid in the best experiment presented in Table 4 Hunter fibroblasts (which have a--iduronidase but not Hunter factor) had only slight activity, whereas a mixture of the two caused the release of as much iduronic acid as did the normal extract (Table 5) . DISCUSSION The results demonstrate that the Hunter corrective factor has sulfoiduronate sulfatase activity. It is unlikely that the sulfatase is a chance contaminant of the admittedly impure factor preparation, since it is specifically absent from extracts of Hunter fibroblasts.
We were surprised to find that acetone-powder extracts of normal fibroblasts did not release more 35SO4t from [n5S]-mucopolysaccharide than did the purified Hunter factor. These extracts contain several of the enzymes necessary for mucopolysaccharide degradation, such as a-L-iduronidase and ,3-glucuronidase (6, 11) , as well as the sulfoiduronate sulfatase.
Presumably, one or more of the unknown degradative enzymes (e.g., hydrolases for the 0-sulfated N-acetylgalactosamine residues of dermatan sulfate) is inactivated during preparation or assay of the acetone-powder extract.
Hunter patients store and secrete both dermatan sulfate and heparan sulfate. Sulfoiduronate residues have been well characterized in mammalian dermatan sulfate and heparin (12) (13) (14) (15) . They have not been reported in heparan sulfate. That, however, is probably because heparan sulfate is poorly studied; it is generally assumed to be similar to heparin (22, 23) , the difference being primarily in molecular size and shape (larger and more branched molecule in heparan sulfate) and ratio of N-acetylated to N-sulfated glucosamine (higher in heparan sulfate 11).
Not all sulfated iduronic-acid residues are available to the sulfatase. We speculate that the unavailable ones are buried within the molecule. This hypothesis is consistent with the finding of a disulfated disaccharide at the nonreducing end of dermatan sulfate isolated from Hunter fibroblasts but not A disulfated disaccharide containing iduronic acid has been found in the urine of a Hunter patient (27) . Such a fragment could result in vivo from the action of an endoglycosidase (e.g., hyaluronidase) on dermatan sulfate.
The clinical consequences of sulfoiduronate sulfatase deficiency are, on the whole, similar to those of a-iiduronidase deficiency. The severe and mild forms of the Hunter syndrome have as their counterpart the Hurler and Scheie syndromes, respectively (1, 28) . There is, however, one consistent phenotypic difference between the two enzyme de-1 I Because of the large proportion of sulfated iduronic-acid residues in heparin, it is puzzling that this polymer should not be stored and excreted in the Hunter syndrome. Although "heparinlike" fractions have been reported among the mucopolysaccharides of Hurler and Sanfilippo patients these are not considered "true" heparin but rather degradation products of heparan sulfate (24, 25) . Perhaps man, in contrast to other mammals, does not synthesize heparin. Experimental data on the subject are sparse (e.g., ref. 26 ).
ficiencies. a-IIduronidase deficiency is always associated with cloudy corneas, whereas corneas remain clear in the Hunter syndrome. One must presume that corneal mucopolysaccharides do not require Hunter factor for degradation, and, therefore, that they are devoid of sulfoiduronate residues.
